Access to anti-retroviral drugs, male in Botswana

Botswana: Access to anti-retroviral drugs, male was 92.0% in 2024. ◆ Volatile

Latest (2024)
92.0%
Change on year
up 3.4%
World rank
11th
of 141 countries
All-time high
92.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Botswana, 2000–2024

0204060801002000201220242000: 0 %2001: 1 %2002: 3 %2003: 7 %2004: 14 %2005: 21 %2006: 28 %2007: 33 %2008: 41 %2009: 43 %2010: 48 %2011: 53 %2012: 56 %2013: 63 %2014: 63 %2015: 67 %2016: 70 %2017: 73 %2018: 76 %2019: 79 %2020: 83 %2021: 87 %2022: 88 %2023: 89 %2024: 92 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, male in Botswana stood at 92.0%. That is the highest value across all 25 years on record.

The figure is up 3.4% on the previous year and up 46.0% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Botswana peaked at 92.0% in 2024 and was at its lowest, 0.0%, in 2000.

That places Botswana 11th out of 141 countries with data for 2024, putting it in the top 10%.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Botswana, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Botswana, 2000 to 2024.
Year % Change
2000 0.0%
2001 1.0%
2002 3.0% +200.0%
2003 7.0% +133.3%
2004 14.0% +100.0%
2005 21.0% +50.0%
2006 28.0% +33.3%
2007 33.0% +17.9%
2008 41.0% +24.2%
2009 43.0% +4.9%
2010 48.0% +11.6%
2011 53.0% +10.4%
2012 56.0% +5.7%
2013 63.0% +12.5%
2014 63.0% +0.0%
2015 67.0% +6.3%
2016 70.0% +4.5%
2017 73.0% +4.3%
2018 76.0% +4.1%
2019 79.0% +3.9%
2020 83.0% +5.1%
2021 87.0% +4.8%
2022 88.0% +1.1%
2023 89.0% +1.1%
2024 92.0% +3.4%

Averages by decade

DecadeAverage LowestHighest Years
2000s 19.1% 0.0% 43.0% 10
2010s 64.8% 48.0% 79.0% 10
2020s 87.8% 83.0% 92.0% 5

Countries ranked near Botswana

  1. 12 Spain 91.0% compare
  2. 13 Burundi 90.0% compare
  3. 13 Malawi 90.0% compare
  4. 13 Namibia 90.0% compare
  5. 13 Switzerland 90.0% compare

See the full ranking of 160 places →

More gender data for Botswana

All data for Botswana →

Frequently asked questions

What is access to anti-retroviral drugs, male in Botswana?
Access to anti-retroviral drugs, male in Botswana was 92.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Botswana?
The highest recorded value was 92.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Botswana?
The lowest recorded value was 0.0% in 2000.
How does Botswana rank for access to anti-retroviral drugs, male?
Botswana ranks 11th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Botswana?
Over the last ten years it is up 46.0%. The long-run trend across the full record is volatile.
Where does this Botswana data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Botswana. Statizoid, drawing on UNAIDS estimates. Retrieved 06 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/botswana/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/botswana/">Access to anti-retroviral drugs, male in Botswana</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.